A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Gregory J. Riely
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Infinity; Merck; Novartis; Pfizer
Julie R. Brahmer
Consultant or Advisory Role - Genentech
David Planchard
No relevant relationships to disclose
Lucio Crinò
No relevant relationships to disclose
Robert Charles Doebele
Honoraria - Abbott Laboratories; Pfizer
Research Funding - ImClone Systems; Lilly; Pfizer
Luis Alberto Mas Lopez
No relevant relationships to disclose
Scott N. Gettinger
No relevant relationships to disclose
Christian Schumann
No relevant relationships to disclose
Xiaoyun Li
Employment or Leadership Position - Merck
Stock Ownership - Merck
Barbara McCormick Atkins
Employment or Leadership Position - Merck
Stock Ownership - Merck
Scot Ebbinghaus
Employment or Leadership Position - Merck
Stock Ownership - Merck
Rafael Rosell
No relevant relationships to disclose